Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
1240 - 1243
MetadataShow full item record
Lenalidomide ((LEN) Revlimid; Celgene Corporation, Summit, NJ, USA), an oral immunomodulatory agent, demonstrated activity in phase 2 trials in patients with chronic lymphocytic leukemia (CLL) in front-line therapy1, 2 and in patients with relapsed and/or refractory disease.3, 4 An open-label, randomized, multicenter, phase 3, parallel-group study was conducted evaluating LEN as first-line therapy for elderly patients (65 years) with CLL (the ORIGIN trial (NCT00910910)). Chlorambucil (CHB), a standard front-line therapy for elderly patients at trial initiation, was used as a comparator.5, 6, 7
AuthorsChanan-Khan, A; Egyed, M; Robak, T; Martinelli de Oliveira, FA; Echeveste, MA; Dolan, S; Desjardins, P; Blonski, JZ; Mei, J; Golany, N; Zhang, J; Gribben, JG